ESMO - European Society for Medical Oncology

📢Summer alert: Sunscreens are crucial for protecting our skin from harmful UV exposure, but they can also enter waterways and harm the ecosystem. There is no perfect sunscreen that is 100% safe for the environment and provides the highest level of skin protection. However, we can take steps to balance the risks and benefits of sunscreen use. In the #OneHealth column on #ESMODailyReporter, Paweł Sobczuk discusses how we can make informed decisions to protect both our health and that of the environment. 🔗https://ow.ly/9Vc050SK3Ab

📣 #ESMOImmuno24: Don’t miss your chance for global recognition. Present your research to an international audience of top-tier scientists, clinicians, and industry experts. ⏰ Deadline: 1 October 2024 ✅Networking: Connect with leading researchers, potential collaborators, and industry pioneers. ✅Professional Growth: Gain visibility and enhance your profile within the scientific community. ✅Publication Opportunity: Accepted abstracts, including late-breaking abstracts, will be published online only in ESMO IOTECH. We welcome submissions on a wide range of #ImmunoOncology topics, including: #BiomarkerDevelopment Cell therapy/Immune engineering #ClinicalPractice Therapeutic development #Tumour biology and tumour microenvironment Miscellaneous 🔗 https://ow.ly/b4lE50SHT8K

📣For ESMO members: Breaking Science in #GastrointestinalCancers: Kohei Shitara talks about the Perioperative pembrolizumab plus chemotherapy in locally-advanced gastric/GEJ cancer. 👉 Don't miss this video and others from the series on OncologyPRO. 🔗 https://ow.ly/70cr50SHUhk

📣 #ESMO4Climate: As we prepare for #ESMO24, ESMO encourages all delegates to travel in the most climate-friendly way possible and consider taking the train to Barcelona whenever possible. Our local partner is ready to assist with train bookings, ensuring your journey is both sustainable and convenient. 🚆 Find out more about the #TrainToESMO initiative and the available travel discounts. Together, we can have a positive impact and ensure a better future for everyone. 🔗 https://ow.ly/6SVl50SGUbu

📣 ESMO is in the process of globalising its Patient Advocates Working Group (PAWG) to identify the challenges and opportunities facing patients with cancer and develop a global patient strategy to contribute tangibly to the delivery of sustainable cancer care worldwide. Members of the PAWG will be required to: ✅ Represent the views of their parent organisation on the ESMO PAWG for an initial 2-year term. ✅ Attend quarterly meetings – 3 virtual and 1 in person at the ESMO Congress. ✅ Assist ESMO staff with the review, analysis and drafting of policy papers. ✅ Develop the program for the Patient Advocacy tracks at ESMO’s European and Asian congresses. ✅ Share their expertise in the development of ESMO’s Clinical Practice Guidelines and other resources. ✅ Upon request, represent ESMO at both internal and external events. ✅ Undertake additional tasks flowing from the development of the Global Patient Strategy. ⏰ Interested parties should send their 📨 application by 18:00 CET on 27th September. 👉 More information here: 🔗https://ow.ly/zNmY50SHfxY

📣 For ESMO members: Breaking Science in #GastrointestinalCancers. Michel P. Ducreux presents his findings on Sequences of regorafenib and trifluridine/tipiracil after failure of standard therapies for mCRC. 👉 Explore this video and the entire series on OncologyPRO now. 🔗 https://ow.ly/guAY50SFi6l

📣 Registration is now open for the webinar based on the ESMO Guidelines developed with EURACAN. 👉 Secure your place with your free ESMO account and take part in the live Q&A session with the experts 🔗 https://ow.ly/LEoQ50SFc34 Alberto Jacobo Cunquero Tomás Myrto K. Moutafi Paolo Bossi

📣 ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and GU Cancers 2024. ⏰ Application deadline is around the corner, don't miss the opportunity to apply before the 23rd July 2024. 👉 More details here: 🔗 https://ow.ly/vEQR50SFg6A

📣 For ESMO members: Breaking Science in #GastrointestinalCancers. Sara Lonardi shares HRQoL with 1st-line NIVO IPI for MSI-H/dMMR mCRC 👉 Catch this informative video and others on OncologyPRO now: 🔗 https://ow.ly/qoxI50SFaIB

📣 For ESMO members: Breaking Science in #GastrointestinalCancers Maximiliano Gelli shares insights on his presentation about #Chemotherapy and liver transplantation for unresectable CRC metastases. 👉 Watch this video and others from this series on OncologyPRO. 🔗 https://ow.ly/WEHO50SClhZ